The global cell therapy manufacturing industry is poised for rapid growth, with a projected valuation of USD 4,134.48 million in 2023, expected to expand at a robust compound annual growth rate (CAGR) of 14.2%. By the end of 2033, the market is anticipated to reach approximately USD 15,634.67 million, driven by the increasing demand for cell-based therapies and significant advancements in regenerative medicine.
Cell therapy manufacturing plays a vital role in the development of treatments for a wide range of diseases, including cancer, autoimmune disorders, and genetic conditions. The market is particularly propelled by the growing focus on autologous cell therapy, which accounted for about 56.0% of the global market share in 2021. Autologous therapies, where a patient’s own cells are used for treatment, are gaining traction due to their reduced risk of immune rejection and promising outcomes in various clinical applications.
Technological advancements in cell culture, expansion of production capabilities, and improved regulatory frameworks are all contributing to the accelerated growth of the market. Additionally, the rising number of clinical trials and approvals for cell-based therapies is further enhancing the outlook for the sector.
A Comprehensive Full Report – https://www.futuremarketinsights.com/reports/cell-therapy-manufacturing-market
Key Takeaways:
- Market Growth: The global cell therapy manufacturing market is expected to grow at a 14.2% CAGR, reaching USD 15.6 billion by 2033.
- Key Drivers: Increasing demand for autologous cell therapies, technological advancements, and regulatory support are driving market expansion.
- Leading Segment: Autologous cell therapy manufacturing holds the largest market share, representing 56.0% of the global market in 2021.
- Future Outlook: With continued innovation and rising clinical success rates, the cell therapy manufacturing market is set to transform the landscape of regenerative medicine and personalized treatments.
The anticipated growth of the cell therapy manufacturing market reflects its critical role in advancing the future of medicine, offering promising new treatments and improved outcomes for patients with various chronic and complex diseases.
Top Trend Pushing Sales in the Global Cell Therapy Manufacturing Industry
- Rising Practice of Manufacturing Capability Outsourcing
It is challenging and time-consuming for businesses that are not familiar with the cell therapy manufacturing process to build a solid supply chain with the tools and processes required to satisfy consumer demand.
Companies that have a strong understanding of the biology of their product, but are unfamiliar with how to transition from a small, manual production to a scaled-up, automated production that serves the needs of hundreds of thousands of patients globally, quickly bridge the gap with the help of an outside organization, such as a contract manufacturing organization (CMO).
Outsourcing of manufacturing capabilities creates growth opportunities for new industry entrants to scale up their products for wide-scale distribution. Additionally, outsourcing saves manufacturers from making investments in large-scale systems and facilitates anticipation of future product delays or regulatory denials.
Competitive Landscape
The global cell therapy manufacturing market is fragmented with the presence of a large number of companies. They are striving persistently to build digital capabilities for cell therapy production. These efforts help them to optimize their business processes and expand their portfolios in the global market.
For instance,
- In April 2022, Lonza added additional integrated capabilities in cell separation, bead removal, and cell binding with the release of its second-generation instrument. It helps in extending the functionality of the company’s Cocoon Platform with magnetic selection capability for cell therapy manufacturing.
- In April 2022, Catalent acquired Erytech Pharma for its industrial-scale cell therapy production plant in Princeton, New Jersey. The arrangement includes an exclusive long-term supply partnership, thereby enabling Catalent to promote red blood cell-derived therapy, eryaspase (GRASPA) by Erytech for acute lymphoblastic leukemia.
Key players
- Merck KGaA
- Avantor, Inc.
- Cell Therapies Pty Ltd
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- BIOCENTRIC
- FUJIFILM Diosynth Biotechnologies
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- WuXi AppTec.
- OXGENE
- Pharmaron
- Aldevron
- FLODESIGN SONICS
- Exothera
Key segments
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
By Region :
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
